Skip to main content

Table 9 Antiangiogenic therapy in combination with other targeting therapies

From: Antiangiogenic therapy for breast cancer

 

Combination

  

Targeting angiogenesis

Targeting HER1 or 2

Reference

Chemotherapy

Monoclonal antibody

Tyrosine kinase inhibitor

mTOR inhibitor

Monoclonal antibody

Tyrosine kinase inhibitor

Hurvitz et al. [89]

      

Dickler et al. [90]

 

Bevacizumab

   

Erlotinib

Dickler et al. [91]

 

Bevacizumab

   

Lapatinib

Blay et al. [92]

  

Sunitinib

 

Trastuzumab

 

Dirix et al. [93]

Docetaxel

 

Sunitinib

 

Trastuzumab

 

Slamon et al. [94]

  

Pazopanib

  

Lapatinib

O'Regan et al. [95]

Paclitaxel

  

Everolimus

Trastuzumab

 

Yardley et al. [96]

   

Ridaforolimus

Trastuzumab

 

Mayer et al. [97]

   

Everolimus

 

Erlotinib

  1. HER, human epidermal growth factor receptor; mTOR, mammalian target of rapamycin.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us